Genentech presented positive results from the Phase III Iclinical trial of Tecentriq in combination with Avastin in unresectable hepatocellular carcinoma (HCC) in people have haven’t received previous systemic therapy. Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply. In the trial, the drug combination showed statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared to the cohort receiving the tyrosine kinase inhibitor sorafenib. Learn More